Sequence Alterations within CYP7B1 Implicate Defective Cholesterol Homeostasis in Motor-Neuron Degeneration  by Tsaousidou, Maria K. et al.
REPORT
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The hereditary spastic paraplegias (HSPs) are a genetically and clinically heterogeneous group of upper-motor-neuron degenerative dis-
eases characterized by selective axonal loss in the corticospinal tracts and dorsal columns. Although numerous mechanisms involving
defective subcellular transportation, mitochondrial malfunction, and increased oxidative stress have been proposed, the pathogenic
basis underlying the neuronal loss is unknown. We have performed linkage analysis to reﬁne the extent of the SPG5 disease locus
and conducted sequence analysis of the genes located within this region. This identiﬁed sequence alterations in the cytochrome
P450-7B1 (CYP7B1) associated with this pure form of HSP. In the liver, CYP7B1 offers an alternative pathway for cholesterol degradation
and also provides the primary metabolic route for the modiﬁcation of dehydroepiandrosterone neurosteroids in the brain. These
ﬁndings provide the ﬁrst direct evidence of a pivotal role of altered cholesterol metabolism in the pathogenesis of motor-neuron
degenerative disease and identify a potential for therapeutic intervention in this form of HSP.The hereditary spastic paraplegias (HSPs [MIM 182601])
encompass a clinically heterogeneous group of neurode-
generative diseases characterized by a progressive degener-
ation of upper motor neurons.1 The cardinal clinical
feature of lower extremity weakness and spasticity may
occur in isolation (‘‘pure’’ HSP) or be accompanied by other
symptoms including mental retardation, cerebellar ataxia,
optic and peripheral neuropathy, and thin corpus cal-
losum.2 The neuropathologic hallmark of HSP is axonal
degeneration of neurons of the corticospinal tracts and
the dorsal columns, with relative preservation of neuronal
cell bodies.
HSP is genetically heterogeneous with >38 loci (HGNC)
encompassing all modes of inheritance.3 Although autoso-
mal-recessive forms of HSP are often associated with clini-
cally complex phenotypes, mutations within a few genes
underlie pure forms of the disease. One of the most com-
mon of these appears to be the ﬁrst pure autosomal-reces-
sive HSP locus deﬁned, SPG5 (MIM 270800), located on
chromosome 8q12.3, to which a number of families have
subsequently been mapped.4–8 However, the precise
nature of the causative gene has remained elusive.
Although several genes have now been identiﬁed for
the various forms of HSP, the mechanisms underlying axo-
nal degeneration and the tissue speciﬁcity of the pheno-
type are poorly understood. The genes identiﬁed to date
appear to have diverse functions implicating a range of pu-510 The American Journal of Human Genetics 82, 510–515, Februarytative disease mechanisms including defective subcellular
transportation, mitochondrial malfunction, and oxidative
stress.9 Although previously not implicated in HSP, some
other neurodegenerative diseases including Niemann-
Pick type C (NPC [MIM 257220]) and cerebrotendinous
xanthomatosis (CTX [MIM 213700]) are thought to be
associated with defects in cholesterol metabolism.10–13
In the liver, primary bile acids required for normal absorp-
tion of lipids and lipid-soluble vitamins are formed from
cholesterol either through the ‘‘neutral pathway’’ involv-
ing the 7a-hydroxylase CYP7A1, considered to be quanti-
tatively most important in humans, or the ‘‘alternate/
acidic pathway’’ involving the related 7a-hydroxylase
CYP7B1.14 These hydroxylases are also key molecules
for the metabolism of brain cholesterol; because there is
little or no transfer of cholesterol across the blood-brain
barrier, most cholesterol is produced in the brain locally,
and there is a precise balance between the biosynthesis,
storage, and catabolism of cholesterol metabolites. In
the brain, CYP7B1 also provides the primary metabolic
route for cholesterol derivatives dehydroepiandrosterone
(DHEA) and related hydroxysteroids via 7a-hydroxylation
(Figure 1).15 Here, we report mutations within CYP7B1
(MIM 603711) associated with a pure form of HSP, which
deﬁnes defective cholesterol metabolism as the likely path-
ogenic cause and identiﬁes a potential therapeutic strategy
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We have previously shown a reﬁnement of the locus for
this gene in a large English family to the location between
markers D8S589 and D8S543 encompassing 23.6 cM at
chromosome 8q12.3.8 In order to more precisely position
the interval-deﬁning proximal and distal recombination
events in this family (family 1), we investigated additional
polymorphic microsatellite markers at each site. Geno-
types of microsatellite markers were determined by PCR
ampliﬁcation and subsequent analysis by polyacrylamide
gel electrophoresis (PAGE) and visualized by silver staining
as previously described.16 Genotyping and haplotype
analysis more precisely deﬁned the ﬂanking markers as
D8S1115 (proximal) andD8S1795 (distal; data not shown).
Combined with very recent information which further
reﬁnes the proximal boundary as marker D8S1113,5 this
results in a reﬁnement of the SPG5 critical interval from
~24 cM to 11cM a region encompassing ~40 transcripts. In-
tronic, exon-ﬂanking primers were designed to amplify
and sequence coding exons and associated splice junctions
of genes located in the critical interval, with sequencing
protocols as previously described.16 Systematic sequence
analysis of the genes located within the interval revealed
a 1088C > T (S363F) substitution in exon 5 of CYP7B1, lo-
cated in the middle of this region (National Center for Bio-
technology Information [accession number NM_004820]).
Subsequent sequence analysis of this gene in ﬁve addi-
tional families (families 2–6) revealed nucleotide changes
in all pedigrees (see Figure 2). Of these ﬁve families, fami-
lies 2–4 have been previously presented and demonstrated
to show linkage to the SPG5 locus.4 The phenotype of
these families as well as in families 1, 5, and 6, can brieﬂy
be summarized as a pure form of HSP including posterior
column sensory impairment as evidenced by diminished
vibration sensation and proprioception and some degree
of bladder dysfunction. The age of onset was variable in
all families ranging from 1 to 40 years of age. Amyotrophy,
or evidence of cerebellar or cerebral cortex dysfunction,
was not present in any of the families examined. All
samples were taken with LREC-approved consent.
The variants identiﬁed included four distinct nonsynon-
ymous mutations in ﬁve of the families tested, all present
in the coding sequence and in a homozygous state inFigure 1. A Simplified Overview of the
Major Bile-Acid and Neurosteroid Bio-
synthetic Pathways
The bile-acid pathway is indicated in blue,
and the neurosteroid pathway is indicated
in red.
affected individuals (1088C > T
[S363F] in family 1, 647T > C [F216S]
in family 2, 1250G > A [R417H] in
families 3 and 4 and 169G > A
[G57R] in family 6). Sequencing of
the unaffected family members and
parents of affected individuals con-The Ameﬁrmed that the variant alleles segregated with the disease.
The single sporadic case (family 5) with a pure HSP pheno-
type was also identiﬁed and screened and was found to be
homozygous for a nonsense mutation, 1162C > T
(R388X). Each mutation was not found in 500 control
chromosomes.
The mutations all disrupt residues that are highly con-
served throughout evolution; G57 and R417 are invariant
in all species examined, F216 is conserved in all but puffer-
ﬁsh, and S363 is conserved in human, gorilla, monkey, and
pufferﬁsh (Figure 2). An evaluation of the likely outcome of
the missense mutations was investigated by NetPhos 2.0.
Two of the mutations are likely to affect phosphorylation
of CYP7B1. The serine at position 363 is strongly predicted
to be phosphorylated (NetPhos score 0.985). Also, the sub-
stitution of the phenylalanine at position 216 for a serine
creates a putative phosphorylation site that is predicted
to be themost likely phosphorylated residue in themutant
molecule, assuming that it is expressed (NetPhos score of
0.997).
The identiﬁcation of mutations in CYP7B1 associated
with HSP presented here provides the ﬁrst direct evidence
for abnormalities in cholesterol metabolism in the patho-
genesis of motor-neuron degeneration. Levels of choles-
terol in the human brain and spinal cord are particularly
high, and as such, neuronsmaywell be particularly suscep-
tible to abnormalities in cholesterol homeostasis.17 Muta-
tions were deﬁned in all families displaying linkage to
the SPG5 locus. The clinical phenotype of the families
in whom we identiﬁed CYP7B1 mutations is that of a
pure (uncomplicated) form with progressive spastic para-
plegia, with variable bladder and sensory (loss of proprio-
ception and vibration sense) involvement. Age of onset
showed both interfamilial and intrafamilial variation
with a range of 1 to 40 years. Those patients with long
disease duration required walking aids, and a few were
wheelchair dependent. Although the genetic defect re-
mains to be clariﬁed, a recent study reported two families
linked to SPG5 in which the HSP was associated with
mild cerebellar signs in individuals with long disease dura-
tion.5 Should CYP7B1 mutations subsequently be de-
scribed in these patients, this would suggest that therican Journal of Human Genetics 82, 510–515, February 2008 511
phenotype of CYP7B1-associated HSPmay be broader than
the pure presentation in the cases documented here. Such
phenotypic variability is not unusual, and complicated
phenotypes have been reported previously for autosomal-
recessive (SPG7 [MIM 607259], SPG27 [MIM 610244]) as
well as autosomal-dominant (SPG4 [MIM 604277]) forms
of HSP.18–20
The mutations identiﬁed here are likely to be highly
detrimental to CYP7B1 functionality. Phosphorylation
has previously been shown to act as an important func-
tional regulatory switch for a number of cytochrome
p450molecules,21 and the S363F and F216S CYP7B1muta-
tions are predicted to abolish and create novel phosphory-
lation sites, respectively. Importantly, one of themutations
identiﬁed here (R388X) has been deﬁned previously and
shown to result in loss of function of CYP7B1.22 Whereas
the phenotype of our patient solely involves that of mo-
tor-neuron degeneration with no other features, the previ-
ous study demonstrated homozygosity for the R388X mu-
tation associated with a severe liver disease in a neonate
who presented with severe cholestasis, cirrhosis, and liver
synthetic failure and who died at the age of 6 months.22
Themechanism of liver injury in this patient was proposed
to be due to the accumulation of hepatotoxic monohy-
droxy bile acids exacerbated by a lack of primary bile acids.
A probable explanation for this phenotypic discrepancy
may be provided by the serum and urine principal oxyster-
ols analysis that revealed hugely increased levels of512 The American Journal of Human Genetics 82, 510–515, Februarysubstrates in the affected neonate (in particular 27-hydrox-
ycholesterol) but the complete absence of 7a-hydroxycho-
lesterol. This latter ﬁnding is puzzling given that sequence
analysis of the six coding exons of the CYP7A1 (MIM
118455) gene, which is responsible for production of 7a-
hydroxycholesterol via the neutral pathway, was thought
to be normal in this child. These ﬁndings were understand-
ably interpreted to suggest that in early human develop-
ment, bile-acid synthesis occurs mainly via the alternate
CYP7B1 pathway and is essential for normal liver develop-
ment. Other studies show that patients with a homozygous
deletion mutation in CYP7A1, which results in loss of the
active site and enzyme function, survive and display high
levels of hepatic cholesterol content and a markedly deﬁ-
cient rate of bile-acid excretion. These patients also display
evidence for upregulation of the alternative bile-acid path-
way CYP7B1,23 a situation that is also mirrored in studies
of murine Cyp7a1 knockouts.24–26 Taken together with
the ﬁndings of our study, it seems likely that the loss of
one 7a-hydrolase pathway may be compensated for, at
least in part, by the remaining pathway. Consequently,
perhaps the best explanation for the discrepancy between
the phenotype of the CYP7B1 mutations presented here
and that of the severe neonatal liver disease is that in the
latter situation, the fatal liver disease in fact arises because
of loss of function of both a-hydroxylating enzymes. This
could be mediated through other sequence variants either
within regions of the CYP7A1 gene not examined in thisFigure 2. Family Trees and DNA Sequence Chromatographs Are Indicated by the Red Boxes, and Conservation of Affected Amino
Acid Residues Is Shown in the Blue Box2008
individual or at a distinct locus important for CYP7A1
function, perhaps within a gene encoding a CYP7A1 co-
factor, thereby resulting in loss of function of both 7-
hydroxylating enzymes. Such a result could explain the
complete absence of 7a-hydroxycholesterol (it is notewor-
thy that this child was the offspring of a consanguineous
ﬁrst-cousin union). When considered together, these fac-
tors are consistent with the notion that the production
of 7a-hydroxycholesterol (via the classic CYP7A1 path-
way) is sufﬁcient for normal liver development and func-
tion and that loss of function of CYP7B1 results speciﬁcally
in upper-motor-neuron degeneration.
Interestingly, mice with disrupted Cyp7b1 have previ-
ously been generated, and although plasma and tissue
levels of 27-hydroxycholesterol were markedly elevated,
these animals developed normally and were grossly indis-
tinguishable from wild-type mice.27 A lack of a motor-neu-
ron phenotype in these animals may reﬂect their age of ex-
amination. Previous studies of another mouse model of
HSP (paraplegin-SPG7 [MIM 607259-MIM 602783]) have
shown that the ﬁrst features of neurodegeneration occur
relatively late (after 8–12 months of age) and that paraple-
gin-deﬁcient mice ultimately become affected by a distal
axonopathy of spinal and peripheral axons, characterized
by axonal swelling and degeneration.28 Consequently, be-
cause a motor-neuron phenotype associated with Cyp7b1
knockout would not necessarily be predicted, it is possible
that any features may have been subtle and late in onset
and have occurred after the mice evaluation that took
place at 3–4months of age.27 Evidence to show that abnor-
mal oxysterol levels may be responsible for motor-neuron
degeneration in mice is provided by studies of liver X re-
ceptor a (LXRa) null mice. LXRa is a ligand-activated recep-
tor, which plays an important role in the regulation of
Cyp7a1 and Cyp7b1 function, and null mutation of this
gene results in an adult-onset motor-neuron degenerative
phenotype.29 This is associated with lipid accumulation
and a selective loss of lower motor neurons associated
with impaired motor function in animals from 7 months
of age.
Cytochrome P450s have been detected in neurons,30
and it is of note that a recent study utilizing monoclonal
antibodies speciﬁc for CYP7B1 detected particularly high
expression in pyramidal cells of human hippocampal sec-
tions, consistent with an important role in motor neurons
that speciﬁcally degenerate in HSP.31 DHEA is converted
to 7-OH-DHEA by CYP7B1, and there is growing evidence
to suggest that this group of neurosteroids act as neuropro-
tective factors and can reduce ischemia-induced neurode-
generation in both in vitro and in vivo models.32 By using
a model of hypoxia that produces an injury similar to mild
ischemia in rat hippocampal slice cultures, a recent study
revealed that these 7-hydroxy metabolites strongly protect
against neurodegeneration of rat hippocampal CA1 pyra-
midal cells.32 This neuroprotection was thought to be de-
pendent on the metabolism of the steroid so that efﬁcacy
was mediated by long-term modiﬁcation of intracellularThe Ameprocesses. Consequently, as well as possible neurotoxicity
associated with aberrant oxysterol levels, the neurodegen-
eration associated with the CYP7B1 mutation may also be
associated with a loss of neuroprotective function of
DHEA-related neurosteroids.
Interestingly, the previous association of cerebrotendi-
nous xanthomatosis with mutations in CYP27A (MIM
606530), which produces the 27-hydroxylated substrate
for CYP7B1 action, raises important possibilities for treat-
ment of this form of HSP. Cerebrotendinous xanthomato-
sis characteristically occurs in late childhood or early adult-
hood and is caused by the accumulation of cholesterol and
cholestanol in various tissues.33 As well as tendon xantho-
mata, cataracts, and atherosclerosis, symptoms include
dementia andmotor dysfunction including spastic parapa-
resis.34 Early diagnosis and treatment with chenodeoxy-
cholic acid, which normalizes the level of the cholesterol
precursor, results in a reduction of cholestanol-containing
xanthomas in the brain and contributes to a better progno-
sis by preventing the progression of neurological symp-
toms.35 Our ﬁndings suggest that the adoption of a similar
strategy here may well offer a potentially important thera-
peutic advance for this debilitating form of motor-neuron
degenerative disease.Acknowledgments
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